… ProQR to Present Results from Phase 1/2 Trial of QR-421a for … & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … “Investors and Media” section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Announces Conference Presentations for Axiomer® RNA … the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in May. Presentation at the TIDES 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA …
… ProQR Receives Fast Track Designation from FDA for QR-421a … & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in …
… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
… ProQR Announces Results for the Fourth Quarter and Full Year … of 2017 and Business Update QR-110 for LCA 10 In April, ProQR’s QR-110 for Leber’s congenital amaurosis 10 (LCA 10) … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
